Organization (Industry)
Orion Corporation, Orion Pharma
ClinicalTrials.gov lists Orion Corporation, Orion Pharma as lead sponsor of 101 trials. It has 19 active development programs and 24 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Unknown author Unknown author, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Orion Corporation, Orion Pharma: 101 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (48)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Asthma | 22 |
| Parkinson Disease | 12 |
| Prostatic Neoplasms | 11 |
| Heart Failure | 7 |
| Pulmonary Disease, Chronic Obstructive | 5 |
Showing 5 of 48 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 3 |
| 2023 | 5 |
| 2022 | 2 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 7 |
| 2018 | 7 |
| 2017 | 7 |
| 2016 | 9 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (19)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Levosimendan | Amyotrophic Lateral Sclerosis | Phase 3 | 2 |
| Tasipimidine | Sleep Initiation and Maintenance Disorders | Phase 2 | 1 |
| Gemcitabine (GEM) and Nab-paclitaxel | Lung Neoplasms | Phase 1/2 | 1 |
| Gemcitabine (GEM) and Nab-paclitaxel | Pancreatic Neoplasms | Phase 1/2 | 1 |
| Gemcitabine (GEM) and Nab-paclitaxel | Mesothelioma | Phase 1/2 | 1 |
Showing 5 of 19 active programs.
Approved assets (24)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Levosimendan | 6 |
| DEXMEDETOMIDINE | 5 |
| Stalevo | 5 |
| Levodopa / Carbidopa | 4 |
| Entacapone | 3 |
Showing 5 of 24 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 36% hit target (n=22) | 38% on time (n=21) |
Journals published in (56)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Critical care (London, England) | 4 |
| Future oncology (London, England) | 3 |
| The New England journal of medicine | 3 |
| Atherosclerosis plus | 2 |
| European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery | 2 |
Showing 5 of 56 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 19 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 9 | 2025-08-22 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Orion Corporation | Kuopio, FI | EMA |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Icon Plc | Uses vendor | 1 |
| PRA Health Sciences | Uses vendor | 1 |
| Rheumatism Foundation Hospital | Co sponsors trial with | 1 |
Latest dated events (170)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-22 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2024-11-07 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2024-09-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 170 events.
Biomarker capability evidence (133)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGT | Trial collaborator | Named in trial inclusion criteria |
| AR | Trial sponsor | Named in trial inclusion criteria |
| AR | Trial sponsor | Named in trial inclusion criteria |
| CREBBP | Trial collaborator | Named in trial inclusion criteria |
| CTLA4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 133 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.